Heartflow raised US$317 million in its initial public offering (IPO), pricing shares at US$19 each, which is above its marketed range.

The company, based in Mountain View, California, develops AI software for diagnosing and managing coronary artery disease.

Heartflow sold 16.7 million shares in the IPO, after increasing the size and price range from earlier plans.

At the IPO price, the company is valued at US$1.5 billion, based on its filings.

The listing follows recent IPOs of medical device firms Shoulder Innovations and Carlsmed, whose shares now trade below their offering prices.

For the quarter ending March 31, Heartflow reported revenue of US$37.2 million and a net loss of US$32.3 million, compared to US$26.8 million in revenue and a US$20.9 million net loss a year earlier.

JP Morgan Chase & Co., Morgan Stanley, and Piper Sandler Cos. led the offering.

Shares are expected to begin trading Friday on the Nasdaq Global Select Market under the symbol HTFL.

🔗 Source: Bloomberg

🧠 Food for thought

1️⃣ Clinical validation proves crucial for medical device IPO success

HeartFlow’s strong IPO performance stands in sharp contrast to recent medical device failures, largely due to robust clinical evidence supporting its technology.

The company’s AI platform demonstrated significant clinical impact in the ADVANCE Registry study, modifying treatment recommendations in 66.9% of cases compared to traditional imaging alone1.

More importantly, patients with HeartFlow’s AI-derived measurements had dramatically different outcomes. Those with concerning readings showed only 14.4% false positives during follow-up procedures, compared to 43.8% for patients with normal readings1.

This clinical validation likely explains why HeartFlow priced above its marketed range at $19 per share, while recent medical device IPOs like Shoulder Innovations and Carlsmed are trading below their offering prices.

The 5,083-patient international study provides the kind of real-world evidence that investors increasingly demand from medical technology companies before committing capital.